(RMD) ResMed - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7611521078
RMD EPS (Earnings per Share)
RMD Revenue
RMD: Sleep, Respiratory, Diagnostic, Monitoring, Management, Software,
ResMed Inc. is a leading global provider of innovative healthcare solutions, specializing in the development, manufacture, and marketing of medical devices and cloud-based software applications for the diagnosis and treatment of respiratory disorders, including sleep apnea. The companys product portfolio includes a range of diagnostic devices, such as ApneaLink Air and NightOwl, as well as therapy management solutions like myAir and AirView, which enable remote monitoring and patient engagement.
ResMeds software solutions, including Brightree, MatrixCare, and HEALTHCAREfirst, cater to a diverse range of healthcare providers, from home medical equipment suppliers to senior living and hospice organizations. The companys out-of-hospital software solutions are designed to streamline clinical workflows, improve patient outcomes, and enhance operational efficiency. With a strong presence in the global healthcare market, ResMed has established a network of distributors and direct sales forces to market its products to sleep clinics, home healthcare dealers, and hospitals.
From a technical analysis perspective, ResMeds stock (RMD) is currently trading at $244.03, slightly below its 20-day simple moving average (SMA) of $245.85. The stock has been oscillating around its 50-day SMA of $230.53 and 200-day SMA of $235.71, indicating a potential bullish trend. With a relatively low average true range (ATR) of 2.20%, the stock is expected to experience moderate volatility. Given the current support and resistance levels, a potential price target for RMD could be around $256, near its 52-week high.
Fundamentally, ResMeds market capitalization stands at approximately $36.4 billion, with a price-to-earnings (P/E) ratio of 27.85 and a forward P/E of 23.81. The companys return on equity (RoE) is a respectable 25.18%. Considering the current valuation multiples and the companys strong financial performance, it is likely that RMD will continue to attract investor interest. Based on the technical and fundamental data, a forecast for RMD could be a potential price appreciation to around $260-$270, representing a 6-10% upside from current levels, driven by the companys continued innovation and growth in the healthcare technology space.
Additional Sources for RMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
RMD Stock Overview
Market Cap in USD | 36,648m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1995-06-02 |
RMD Stock Ratings
Growth Rating | 28.8 |
Fundamental | 92.4 |
Dividend Rating | 55.5 |
Rel. Strength | 25 |
Analysts | 3.95 of 5 |
Fair Price Momentum | 226.99 USD |
Fair Price DCF | 168.20 USD |
RMD Dividends
Dividend Yield 12m | 0.87% |
Yield on Cost 5y | 1.35% |
Annual Growth 5y | 5.30% |
Payout Consistency | 100.0% |
Payout Ratio | 23.4% |
RMD Growth Ratios
Growth Correlation 3m | 82.5% |
Growth Correlation 12m | 36.7% |
Growth Correlation 5y | 17.2% |
CAGR 5y | 9.68% |
CAGR/Max DD 5y | 0.18 |
Sharpe Ratio 12m | 1.06 |
Alpha | 8.54 |
Beta | 0.788 |
Volatility | 26.90% |
Current Volume | 427.4k |
Average Volume 20d | 657.8k |
As of June 15, 2025, the stock is trading at USD 249.34 with a total of 427,411 shares traded.
Over the past week, the price has changed by -1.13%, over one month by +0.68%, over three months by +13.73% and over the past year by +18.46%.
Yes, based on ValueRay´s Fundamental Analyses, ResMed (NYSE:RMD) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 92.42 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RMD is around 226.99 USD . This means that RMD is currently overvalued and has a potential downside of -8.96%.
ResMed has received a consensus analysts rating of 3.95. Therefor, it is recommend to buy RMD.
- Strong Buy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- Strong Sell: 1
According to our own proprietary Forecast Model, RMD ResMed will be worth about 258.3 in June 2026. The stock is currently trading at 249.34. This means that the stock has a potential upside of +3.58%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 264.5 | 6.1% |
Analysts Target Price | 264.5 | 6.1% |
ValueRay Target Price | 258.3 | 3.6% |